Sumitomo Chemical India H1 Revenue Falls 1% to Rs 1,971 Crore

Sumitomo Chemical India Limited reported revenue of Rs 1,971 crore for the first half of FY27, down 1% year-on-year, while second-quarter revenue fell 2% to Rs 907 crore. The update indicates broadly stable sales in the first six months after the company reported FY26 revenue growth and record profitability.

What did Sumitomo Chemical India report for Q2 and H1 FY27?

Sumitomo Chemical India reported Q2 FY27 revenue of Rs 907 crore, a 2% decline from the corresponding quarter of the previous year. For H1 FY27, revenue stood at Rs 1,971 crore, down 1% year-on-year.

The figures were presented by Managing Director Dr. Suresh Ramachandran during the company’s earnings conference call held on October 27, 2026. The call covered the company’s performance for the second quarter and first half of FY27.

The supplied earnings-call extract does not provide quarterly or half-year profit, margin, volume, segment, export or cash-flow figures. It also does not specify the reasons for the year-on-year revenue decline. Therefore, the disclosed revenue figures are the clearest measure of the operating trend available from the update.

Who spoke at the Sumitomo Chemical India earnings call?

Sumitomo Chemical India’s management team was led by Dr. Suresh Ramachandran, Managing Director, on the earnings call. Kunal Mittal, Executive Vice President, Anil Nawal, Chief Financial Officer, and Deepika Trivedi, Company Secretary and Compliance Officer, were also identified as participants from the management side.

The company had intimated investors and analysts about the October 27 call on October 19, 2026. It noted that the discussion could contain forward-looking statements based on management’s beliefs, opinions and expectations as of the date of the call.

Management stated the reported Q2 and H1 revenue figures during its opening remarks. No detailed official explanation for the 1% decline in half-year revenue or the 2% decline in quarterly revenue appears in the supplied transcript extract.

The available material also does not provide a revised annual outlook, a volume target, or an announced operational plan for the remaining months of FY27. Investors evaluating the update will therefore need the complete call transcript and subsequent financial disclosures for further detail on profitability and business conditions.

How does H1 FY27 compare with Sumitomo Chemical India’s FY26 performance?

The H1 FY27 revenue movement follows a stronger FY26, when Sumitomo Chemical India reported revenue from operations of Rs 3,238 crore, up 3% year-on-year. The company also reported profit after tax of Rs 543 crore for FY26, an increase of more than 7% year-on-year.

FY26 EBITDA was Rs 671 crore, up 6% year-on-year, and the EBITDA margin improved by 64 basis points to 20.7%. Profit before tax was Rs 728 crore, up 7% year-on-year, with a margin of 22.5%.

In Q4 FY26, revenue from operations was Rs 684 crore, up 1% year-on-year. Gross profit for that quarter rose 6% to Rs 289 crore, while gross margin expanded by 223 basis points to 42.3%.

The contrast between FY26’s reported annual growth and the modest revenue decline in the first half of FY27 is relevant because the company had described FY26 as a year of record profitability despite challenging industry conditions. However, the current update does not contain enough information to assess whether H1 FY27 margins or profit have followed the revenue trend.

What does the revenue update mean for investors and operations?

The revenue update shows that Sumitomo Chemical India’s sales were largely stable in H1 FY27, although they were lower than the comparable period a year earlier. The 1% half-year decline is modest in percentage terms, but it follows FY26, when the company delivered 3% revenue growth and higher profitability.

For investors, the key missing data points are the company’s H1 FY27 earnings, margin performance and management commentary on business drivers. These figures would help establish whether the lower revenue has affected operating profitability or whether the company has been able to maintain the margin discipline it reported in FY26.

The supplied material does not identify any changes in product availability, customer demand, pricing, input costs or manufacturing operations. It also does not disclose an impact on employees, communities or customers. As a result, conclusions about the causes or implications of the revenue movement would be premature.

The company’s earlier FY26 call referred to challenging industry conditions and management’s ability to pass on cost increases where possible. It also cautioned that supply execution, logistics and customer affordability could influence volume movements in a changing cost environment. Those comments provide historical context but should not be treated as an explanation for the Q2 or H1 FY27 result.

What should investors track after the H1 FY27 update?

Investors should track Sumitomo Chemical India’s complete Q2 and H1 FY27 disclosures for profit, EBITDA, margin and cash-flow data. These indicators will show whether the modest reduction in revenue has had a corresponding effect on financial performance.

It will also be important to monitor management’s commentary on demand, pricing, costs, supply and customer affordability. The company had previously linked these factors to its ability to meet customer demand and preserve margins, but no current-period update on these issues is included in the supplied excerpt.

The company’s regulatory disclosures show that it publishes earnings-call transcripts and related investor materials through its investor-relations resources. The full transcript of the October 27, 2026 call is therefore the relevant next source for investors seeking detail beyond the headline revenue figures.

Conclusion

Sumitomo Chemical India reported a small year-on-year reduction in revenue during H1 FY27, with sales of Rs 1,971 crore, while Q2 revenue was Rs 907 crore. The update marks a softer top-line comparison after FY26, when revenue, EBITDA and profit after tax all increased, but it does not disclose sufficient current-period earnings data to assess the effect on profitability.

The next point to watch is the company’s detailed Q2 and H1 FY27 financial information and the full earnings-call transcript. Investors will look for management’s disclosures on margins, demand, pricing, costs and operating conditions, along with any guidance for the remainder of FY27.